Tianyin Pharmaceutical 10-Q 14 Feb 14 2014 Q2 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	6 Months Ended
	Dec. 31, 2013	Feb. 14, 2014
Document and Entity Information [Abstract]	'	'
Entity Registrant Name	'TIANYIN PHARMACEUTICAL CO., INC.	'
Entity Central Index Key	'0001362718	'
Amendment Flag	'false	'
Current Fiscal Year End Date	'--06-30	'
Document Type	'10-Q	'
Document Period End Date	31-Dec-13	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q2	'
Entity Filer Category	'Smaller Reporting Company	'
Entity Common Stock, Shares Outstanding	'	29,382,791

Consolidated_Balance_Sheets_Un

Consolidated Balance Sheets (Unaudited) (USD $)	Dec. 31, 2013	Jun. 30, 2013
Current assets:	'	'
Cash and cash equivalents	$31,307,119	$26,827,008
Restricted cash	'	4,536,000
Accounts receivable, net of allowance for doubtful accounts of $103,220 and $102,149 at December 31, 2013 and June 30, 2013, respectively	10,785,253	10,112,718
Inventory	6,037,270	6,036,014
Other current assets	'	313,320
Total current assets	48,129,642	47,825,060
Property and equipment, net	40,506,632	40,603,232
Intangibles, net	21,317,994	21,505,012
Goodwill	212,810	210,600
Total assets	110,167,078	110,143,904
Current liabilities:	'	'
Accounts payable and accrued expenses	1,466,397	1,352,560
Accounts payable - construction related	'	2,723,290
Short-term bank loans	4,583,600	5,929,200
Income tax and other taxes payable	1,196,355	1,442,111
Other current liabilities	472,403	449,062
Total current liabilities	7,718,755	11,896,223
Total liabilities	7,718,755	11,896,223
Stockholders' equity:	'	'
Preferred stock, $0.001 par value, 25,000,000 shares authorized, no shares issued and outstanding as of December 31, 2013 and June 30, 2013, respectively	'	'
Common stock, $0.001 par value, 50,000,000 shares authorized, 29,496,276 shares issued and 29,382,791 shares outstanding as of December 31, 2013 and June 30, 2013, respectively	29,496	29,496
Additional paid-in capital	30,134,852	30,134,852
Treasury stock	-135,925	-135,925
Statutory reserve	7,247,466	6,847,315
Retained earnings	53,825,888	50,967,308
Accumulated other comprehensive income	11,224,655	10,178,358
Total stockholders' equity - Tianyin Pharmaceutical Co., Inc.	102,326,432	98,021,404
Noncontrolling interest	121,891	226,277
Total equity	102,448,323	98,247,681
Total liabilities and equity	$110,167,078	$110,143,904

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical) (Unaudited) (USD $)	Dec. 31, 2013	Jun. 30, 2013
Balance Sheets [Abstract]	'	'
Allowance for doubtful accounts	$103,220	$102,149
Preferred stock, par value	$0.00	$0.00
Preferred stock, shares authorized	25,000,000	25,000,000
Preferred stock, shares issued	'	'
Preferred stock, shares outstanding	'	'
Common stock, par value	$0.00	$0.00
Common stock, shares authorized	50,000,000	50,000,000
Common stock, shares issued	29,496,276	29,382,791
Common stock, shares outstanding	29,496,276	29,382,791

Consolidated_Statements_of_Ope

Consolidated Statements of Operations (Unaudited) (USD $)	3 Months Ended		6 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2012
Statements Of Operations [Abstract]	'	'	'	'
Sales	$13,923,166	$17,603,298	$28,671,714	$33,574,995
Cost of sales	7,705,869	10,799,516	16,460,902	20,527,509
Gross profit	6,217,297	6,803,782	12,210,812	13,047,486
Operating expenses	'	'	'	'
Selling expenses	2,428,675	2,885,087	4,967,919	5,646,525
General and administrative expenses	1,082,395	1,097,854	2,111,161	2,219,387
Research and development	252,014	222,423	503,328	438,353
Total operating expenses	3,763,084	4,205,364	7,582,408	8,304,265
Income from operations	2,454,213	2,598,418	4,628,404	4,743,221
Other income (expenses):	'	'	'	'
Interest income	86,424	31,842	108,734	99,444
Interest expense	-119,821	-113,468	-222,722	-221,872
Total other expenses	-33,397	-81,626	-113,988	-122,428
Income before provision for income taxes	2,420,816	2,516,792	4,514,416	4,620,793
Provision for income taxes	727,757	668,762	1,361,865	1,251,810
Net income	1,693,059	1,848,030	3,152,551	3,368,983
Less: net loss attributable to noncontrolling interest	-50,549	-15,920	-106,180	-36,584
Net income attributable to Tianyin Pharmaceutical Co., Inc.	$1,743,608	$1,863,950	$3,258,731	$3,405,567
Basic and diluted earnings per share	$0.06	$0.06	$0.11	$0.12
Weighted average number of common shares outstanding:	'	'	'	'
Basic and diluted	29,382,791	29,332,791	29,382,791	29,332,791

Consolidated_Statements_of_Com

Consolidated Statements of Comprehensive Income (Unaudited) (USD $)	3 Months Ended		6 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2012
Statements Of Comprehensive Income [Abstract]	'	'	'	'
Net income	$1,693,059	$1,848,030	$3,152,551	$3,368,983
Other comprehensive income	'	'	'	'
Foreign currency translation adjustment	435,429	226,799	10,480,491	114,299
Total other comprehensive income	435,429	226,799	10,480,491	114,299
Total Comprehensive income	2,128,488	2,074,829	4,200,642	3,483,282
Less: Comprehensive income attributable to the noncontrolling interest	-49,912	-15,225	-104,386	-36,249
Comprehensive income attributable to Tianyin Pharmaceutical Co., Inc.	$2,178,400	$2,090,054	$4,305,028	$3,519,531

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	6 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Cash flows from operating activities:	'	'
Net Income	$3,152,551	$3,368,983
Adjustments to reconcile net income to net cash provided by (used in) operating activities:	'	'
Depreciation and amortization	1,297,519	1,171,649
Share-based payments	'	17,730
Changes in current assets and current liabilities:	'	'
Accounts receivable	-563,334	786,045
Inventory	61,748	-1,099,581
Other current assets	314,887	628,465
Accounts payable and accrued expenses	99,102	-319,349
Accounts payable - construction related	-2,736,906	-329,684
Trade notes payable	'	-4,679,585
Income tax payable and other taxes payable	-259,470	-170,821
Other current liabilities	18,527	-33,539
Net cash provided by (used in) operating activities	1,384,624	-659,687
Cash flows from investing activities:	'	'
Additions to property and equipment	'	-1,002,716
Advance payments - construction and equipment	'	-5,298,242
Additions of construction in progress	-367,234	-6,123,118
Acquisition of subsidiary - Hengshuo (HSP)	'	-206,219
Net cash used in investing activities	-367,234	-12,630,295
Cash flows from financing activities:	'	'
Restricted cash	4,558,680	3,537,449
Proceeds from short-term bank loans	4,558,680	'
Repayment on short-term bank loans	-5,958,846	'
Net cash provided by financing activities	3,158,514	3,537,449
Effect of foreign currency translation on cash	304,207	39,891
Net increase(decrease) in cash and cash equivalents	4,480,111	-9,712,642
Cash and cash equivalents - beginning of period	26,827,008	35,152,295
Cash and cash equivalents - ending of period	31,307,119	25,439,653
Supplemental disclosures of cash activities	'	'
Cash paid for interest	222,645	221,872
Cash paid for income taxes	$1,340,918	$1,390,391

Organization_and_Nature_of_Bus

Organization and Nature of Business	6 Months Ended
	Dec. 31, 2013
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
ORGANIZATION AND NATURE OF BUSINESS	'
	Note 1 – Organization and Nature of Business
	Tianyin Pharmaceutical Co., Inc. (the “Company” or “Tianyin”), was established under the laws of Delaware. The Company’s primary business is to research, manufacture, and sell pharmaceutical products in China through its wholly owned subsidiaries.

Basis_of_Presentation_and_Cons

Basis of Presentation and Consolidation	6 Months Ended
	Dec. 31, 2013
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
BASIS OF PRESENTATION AND CONSOLIDATION	'
	NOTE 2 – BASIS OF PRESENTATION AND CONSOLIDATION
	The accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United Stated of America (US GAAP). The unaudited consolidated financial statements include the accounts of Tianyin and its wholly-owned subsidiaries. All inter-company transactions and balances have been eliminated in consolidation. The accompanying unaudited financial statements have been prepared in accordance with US GAAP applicable to interim financial information and the requirements of Form 10-Q and Article 8 of Regulation S-X of the Securities and Exchange Commission. Accordingly, they do not include all of the information and disclosures required by US GAAP for complete financial statements. Interim results are not necessarily indicative of results for a full year. In the opinion of management, all adjustments, which include only normal recurring adjustments, considered necessary for a fair presentation of the financial position and the results of operations and cash flows for the interim periods have been included.
	These interim unaudited consolidated financial statements should be read in conjunction with the consolidated financial statements for the year ended June 30, 2013, included in the Company’s annual report on Form 10-K filed with the U.S. Securities Exchange Commission on September 26, 2013, as not all disclosures required by US GAAP for annual financial statements are presented. The interim consolidated financial statements follow the same accounting policies and methods of computations as the audited consolidated financial statements for the year ended June 30, 2013.
	In preparing the accompanying unaudited consolidated financial statements, we evaluated the period from December 31, 2013 through the date the financial statements were issued for material subsequent events requiring recognition or disclosure. No such events were identified for this period.
	The Company uses the United States dollar (“U.S. Dollar” or “US$” or “$”) for financial reporting purposes. The subsidiaries within the Company maintain their books and records in their respective functional currency, being the primary currency of the economic environment in which their operations are conducted. Assets and liabilities of a subsidiary with functional currency other than U.S. Dollar are translated into U.S. Dollars using the applicable exchange rates prevailing at the balance sheet date. Items on the statements of income and comprehensive income and cash flows are translated at average exchange rates during the reporting period. Equity accounts are translated at historical rates. Adjustments resulting from the translation of the Company’s financial statements are recorded as a component of accumulated other comprehensive income.
	Certain amounts of prior period were reclassified for presentation purpose.

Inventory

Inventory	6 Months Ended
	Dec. 31, 2013
Inventory [Abstract]	'
INVENTORY	'
	NOTE 3 – INVENTORY
	Inventory as of December 31, 2013 and June 30, 2013 consists of the following:
		December 31,		June 30,
		2013		2013
	Raw materials	$	801,455	$	748,296
	Packaging supplies		471,586		369,143
	Work in process		1,840,192		1,871,093
	Finished goods		2,924,037		3,047,482
		$	6,037,270	$	6,036,014

Accounts_Payable_and_Accrued_E

Accounts Payable and Accrued Expenses	6 Months Ended
	Dec. 31, 2013
Accounts Payable and Accrued Expenses [Abstract]	'
ACCOUNTS PAYABLE AND ACCRUED EXPENSES	'
	NOTE 4 – ACCOUNTS PAYABLE AND ACCRUED EXPENSES
	Accounts payable and accrued expenses consist of the following:
		December 31,		June 30,
		2013		2013
	Accounts payable		1,435,949	$	1,206,760
	Accrued expenses		30,448		145,800
	Total	$	1,466,397	$	1,352,560
	The carrying value of accounts payable and accrued expenses approximates their fair value due to the short-term nature of these obligations.

ShortTerm_Bank_Loans

Short-Term Bank Loans	6 Months Ended
	Dec. 31, 2013
Short-Term Bank Loans [Abstract]	'
SHORT-TERM BANK LOANS	'
	NOTE 5 – SHORT-TERM BANK LOANS
	Short-term bank loans consist of the following:
		December 31,		June 30,
		2013		2013
	On September 19, 2012, the Company obtained a loan from China Huaxia Bank, the principal balance was paid in full on September 27, 2013. The interest is calculated using an annual fixed interest rate of 7.2% and paid monthly.		-	$	1,620,000
	On June 21, 2013, the Company obtained a loan from China CITIC Bank, which matures on December 21, 2013. The interest is calculated using an annual fixed interest rate of 6.440% and paid monthly. The loan was secured by the Company’s certificates of deposit, which included in the restricted cash on the Company’s balance sheet. The loan was paid in full in December 2013.		-	$	4,309,200
	On October 28, 2013, the Company obtained a loan from China CITIC Bank, which matures on October 30, 2014 . The interest is calculated using an annual fixed interest rate of 7.2% and paid monthly. The loan was guaranteed by a third party and the Company’s CEO, Mr. Jiang. .	$	4,583,600		-
	Total short-term bank loans	$	4,583,600	$	5,929,200

Income_Taxes

Income Taxes	6 Months Ended
	Dec. 31, 2013
Income Taxes [Abstract]	'
INCOME TAXES	'
	NOTE 6 – INCOME TAXES
	Raygere is incorporated in the British Virgin Islands. Under the corporate tax laws of British Virgin Islands, it is not subject to tax on income or capital gain.
	The operating subsidiary Chengdu Tianyin is a wholly foreign-owned enterprise incorporated in the PRC and subject to PRC Foreign Enterprise Income Tax (“FEIT”) Law. Starting January 1, 2011, the effective tax rate for Chendu Tianyin was between 25% - 30%. As domestic invested companies, the effective tax rates of Tianyin Medicine Trading, HSP and JCM are all between 25% and 30% each from their operations.
	In July 2006, the FASB issued ASC 740 that clarifies the accounting for income taxes by prescribing a minimum probability threshold that a tax position must meet before a financial statement benefit is recognized. The minimum threshold is defined as a tax position that is more likely than not to be sustained upon examination by the applicable taxing authority, including resolution of any related appeals or litigation processes, based on the technical merits of the position. The Company does not recognize any benefits in the financial statements for the fiscal year ended June 30, 2013.

Risk_Factors

Risk Factors	6 Months Ended
	Dec. 31, 2013
Risk Factors [Abstract]	'
RISK FACTORS	'
	NOTE 7 – RISK FACTORS
	The Company's operations are carried out in the PRC. Accordingly, the Company's business, financial condition and results of operations may be adversely influenced by the political, economic and legal environments in the PRC as well as by the general state of the PRC’s economy. Specifically, the Company's business may be negatively influenced by changes in governmental policies with respect to laws and regulations, anti-inflationary measures, currency conversion and remittance abroad, and rates and methods of taxation, among other things.

Risk_of_Concentrations_and_Cre

Risk of Concentrations and Credit Risk	6 Months Ended
	Dec. 31, 2013
Risk of Concentrations and Credit Risk [Abstract]	'
RISK OF CONCENTRATIONS AND CREDIT RISK	'
	NOTE 8 – RISK OF CONCENTRATIONS AND CREDIT RISK
	For the six months ended December 31, 2013, no sales to single customer accounted for more than 10% of the Company’s sales. Sales to one customer accounted for 13% of the Company’s total sales for the six months ended December 31, 2012.
	Purchases from four vendors accounted for 18%, 14%, 12% and 11% of the company’s total purchases for the six months ended December 31, 2013, respectively. Purchases from one vendor accounted for approximately 46% of the Company’s total purchases for the six months ended December 31, 2012. .
	Financial instruments which potentially subject the Company to credit risk consist principally of cash on deposit with financial institutions. Management believes that the financial institutions that hold the Company’s cash and cash equivalents are financially sound and minimal credit risk exists with respect to these investments.

Earnings_Per_Share

Earnings Per Share	6 Months Ended
	Dec. 31, 2013
Earnings Per Share [Abstract]	'
EARNINGS PER SHARE	'
	NOTE 9 – EARNINGS PER SHARE
	The Company presents earnings per share (“EPS”) on a basic and diluted basis. Basic earnings per share have been computed by dividing net earnings by the weighted average number of common shares outstanding. Diluted earnings per share has been computed by dividing net earnings plus convertible preferred dividends and interest expense (after-tax) on convertible debt by the weighted average number of common shares outstanding including the dilutive effect of equity securities. The weighted average number of common shares calculated for Diluted EPS excludes the potential common stock that would be exercised under the options and warrants granted to officers because the inclusion of the potential shares from these options and warrants would cause an antidilutive effect by increasing the net earnings per share.
		Three Months Ended
		December 31,
		2013		2012
	Net income (numerator for diluted income per share)	$	1,743,608	$	1,863,950
	Less: Dividend attributable to preferred stockholders		-		-
	Net income attributable to common stockholders		1,743,608	$	1,863,950
	(numerator for basic income per share)
	Weighted average common shares		29,382,791		29,332,791
	(denominator for basic income per share)
	Effect of diluted securities:
	Convertible preferred stock		-		-
	Warrants		-		-
	Weighted average common shares		29,382,791		29,332,791
	(denominator for diluted income per share)
	Basic net income per share	$	0.06	$	0.06
	Diluted net income per share	$	0.06	$	0.06
		Six Months Ended
		December 31,
		2013		2012
	Net income (numerator for diluted income per share)	$	3,258,731	$	3,405,567
	Less: Dividend attributable to preferred stockholders		-		-
	Net income attributable to common stockholders		3,258,731	$	3,405,567
	(numerator for basic income per share)
	Weighted average common shares		29,382,791	29,332,791
	(denominator for basic income per share)
	Effect of diluted securities:
	Convertible preferred stock		-		-
	Warrants		-		-
	Weighted average common shares		29,382,791		29,332,791
	(denominator for diluted income per share)
	Basic net income per share	$	0.11	$	0.12
	Diluted net income per share	$	0.11	$	0.12

Basis_of_Presentation_and_Cons1

Basis of Presentation and Consolidation (Policies)	6 Months Ended
	Dec. 31, 2013
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
BASIS OF PRESENTATION AND CONSOLIDATION	'
	BASIS OF PRESENTATION AND CONSOLIDATION
	The accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United Stated of America (US GAAP). The unaudited consolidated financial statements include the accounts of Tianyin and its wholly-owned subsidiaries. All inter-company transactions and balances have been eliminated in consolidation. The accompanying unaudited financial statements have been prepared in accordance with US GAAP applicable to interim financial information and the requirements of Form 10-Q and Article 8 of Regulation S-X of the Securities and Exchange Commission. Accordingly, they do not include all of the information and disclosures required by US GAAP for complete financial statements. Interim results are not necessarily indicative of results for a full year. In the opinion of management, all adjustments, which include only normal recurring adjustments, considered necessary for a fair presentation of the financial position and the results of operations and cash flows for the interim periods have been included.
	These interim unaudited consolidated financial statements should be read in conjunction with the consolidated financial statements for the year ended June 30, 2013, included in the Company’s annual report on Form 10-K filed with the U.S. Securities Exchange Commission on September 26, 2013, as not all disclosures required by US GAAP for annual financial statements are presented. The interim consolidated financial statements follow the same accounting policies and methods of computations as the audited consolidated financial statements for the year ended June 30, 2013.
	In preparing the accompanying unaudited consolidated financial statements, we evaluated the period from December 31, 2013 through the date the financial statements were issued for material subsequent events requiring recognition or disclosure. No such events were identified for this period.
	The Company uses the United States dollar (“U.S. Dollar” or “US$” or “$”) for financial reporting purposes. The subsidiaries within the Company maintain their books and records in their respective functional currency, being the primary currency of the economic environment in which their operations are conducted. Assets and liabilities of a subsidiary with functional currency other than U.S. Dollar are translated into U.S. Dollars using the applicable exchange rates prevailing at the balance sheet date. Items on the statements of income and comprehensive income and cash flows are translated at average exchange rates during the reporting period. Equity accounts are translated at historical rates. Adjustments resulting from the translation of the Company’s financial statements are recorded as a component of accumulated other comprehensive income.
	Certain amounts of prior period were reclassified for presentation purpose.

Inventory_Tables

Inventory (Tables)	6 Months Ended
	Dec. 31, 2013
Inventory [Abstract]	'
Schedule of inventory	'
		December 31,		June 30,
		2013		2013
	Raw materials	$	801,455	$	748,296
	Packaging supplies		471,586		369,143
	Work in process		1,840,192		1,871,093
	Finished goods		2,924,037		3,047,482
		$	6,037,270	$	6,036,014

Accounts_Payable_and_Accrued_E1

Accounts Payable and Accrued Expenses (Tables)	6 Months Ended
	Dec. 31, 2013
Accounts Payable and Accrued Expenses [Abstract]	'
Schedule of accounts payable and accrued expenses	'
		December 31,		June 30,
		2013		2013
	Accounts payable		1,435,949	$	1,206,760
	Accrued expenses		30,448		145,800
	Total	$	1,466,397	$	1,352,560

ShortTerm_Bank_Loans_Tables

Short-Term Bank Loans (Tables)	6 Months Ended
	Dec. 31, 2013
Short-Term Bank Loans [Abstract]	'
Schedule of short-term bank loans	'
		December 31,		June 30,
		2013		2013
	On September 19, 2012, the Company obtained a loan from China Huaxia Bank, the principal balance was paid in full on September 27, 2013. The interest is calculated using an annual fixed interest rate of 7.2% and paid monthly.		-	$	1,620,000
	On June 21, 2013, the Company obtained a loan from China CITIC Bank, which matures on December 21, 2013. The interest is calculated using an annual fixed interest rate of 6.440% and paid monthly. The loan was secured by the Company’s certificates of deposit, which included in the restricted cash on the Company’s balance sheet. The loan was paid in full in December 2013.		-	$	4,309,200
	On October 28, 2013, the Company obtained a loan from China CITIC Bank, which matures on October 30, 2014 . The interest is calculated using an annual fixed interest rate of 7.2% and paid monthly. The loan was guaranteed by a third party and the Company’s CEO, Mr. Jiang. .	$	4,583,600		-
	Total short-term bank loans	$	4,583,600	$	5,929,200

Earnings_Per_Share_Tables

Earnings Per Share (Tables)	6 Months Ended
	Dec. 31, 2013
Earnings Per Share [Abstract]	'
Schedule of earnings per share on a basic and diluted basis	'
		Three Months Ended
		December 31,
		2013		2012
	Net income (numerator for diluted income per share)	$	1,743,608	$	1,863,950
	Less: Dividend attributable to preferred stockholders		-		-
	Net income attributable to common stockholders		1,743,608	$	1,863,950
	(numerator for basic income per share)
	Weighted average common shares		29,382,791		29,332,791
	(denominator for basic income per share)
	Effect of diluted securities:
	Convertible preferred stock		-		-
	Warrants		-		-
	Weighted average common shares		29,382,791		29,332,791
	(denominator for diluted income per share)
	Basic net income per share	$	0.06	$	0.06
	Diluted net income per share	$	0.06	$	0.06
		Six Months Ended
		December 31,
		2013		2012
	Net income (numerator for diluted income per share)	$	3,258,731	$	3,405,567
	Less: Dividend attributable to preferred stockholders		-		-
	Net income attributable to common stockholders		3,258,731	$	3,405,567
	(numerator for basic income per share)
	Weighted average common shares		29,382,791		29,332,791
	(denominator for basic income per share)
	Effect of diluted securities:
	Convertible preferred stock		-		-
	Warrants		-		-
	Weighted average common shares		29,382,791		29,332,791
	(denominator for diluted income per share)
	Basic net income per share	$	0.11	$	0.12
	Diluted net income per share	$	0.11	$	0.12

Inventory_Details

Inventory (Details) (USD $)	Dec. 31, 2013	Jun. 30, 2013
Schedule of inventory	'	'
Raw materials	$801,455	$748,296
Packaging supplies	471,586	369,143
Work in process	1,840,192	1,871,093
Finished goods	2,924,037	3,047,482
Total	$6,037,270	$6,036,014

Accounts_Payable_and_Accrued_E2

Accounts Payable and Accrued Expenses (Details) (USD $)	Dec. 31, 2013	Jun. 30, 2013
Accounts payable and accrued expenses	'	'
Accounts payable	$1,435,949	$1,206,760
Accrued expenses	30,448	145,800
Total	$1,466,397	$1,352,560

ShortTerm_Bank_Loans_Details

Short-Term Bank Loans (Details) (USD $)	Dec. 31, 2013	Jun. 30, 2013
Schedule of short-term bank loans	'	'
Total short-term bank loans	$4,583,600	$5,929,200
Fixed interest rate of 7.2% [Member] | China Huaxia Bank [Member]	'	'
Schedule of short-term bank loans	'	'
Total short-term bank loans	'	1,620,000
Fixed interest rate of 7.2% [Member] | China Citic Bank [Member]	'	'
Schedule of short-term bank loans	'	'
Total short-term bank loans	4,583,600	'
Fixed interest rate of 6.440% [Member] | China Citic Bank [Member]	'	'
Schedule of short-term bank loans	'	'
Total short-term bank loans	'	$4,309,200

ShortTerm_Bank_Loans_Details_T

Short-Term Bank Loans (Details Textual)	0 Months Ended	1 Months Ended	0 Months Ended
	Oct. 28, 2013	Sep. 19, 2012	Jun. 21, 2013
	Fixed interest rate of 7.2% [Member]	Fixed interest rate of 7.2% [Member]	Fixed interest rate of 6.440% [Member]
Short-Term Bank Loans (Textual)	'	'	'
Annual fixed interest rate of short-term bank loans	7.20%	7.20%	6.44%
Maturity date	30-Oct-14	27-Sep-13	21-Dec-13

Income_Taxes_Details

Income Taxes (Details)	6 Months Ended
	Dec. 31, 2013
Chengdu Tianyin Pharmaceutical Co., Ltd. [Member] | Minimum [Member]	'
Income Taxes (Textual)	'
Effective tax rates	25.00%
Chengdu Tianyin Pharmaceutical Co., Ltd. [Member] | Maximum [Member]	'
Income Taxes (Textual)	'
Effective tax rates	30.00%
Chengdu Tianyin Medicine Trading Co., Ltd. [Member] | Minimum [Member]	'
Income Taxes (Textual)	'
Effective tax rates	25.00%
Chengdu Tianyin Medicine Trading Co., Ltd. [Member] | Maximum [Member]	'
Income Taxes (Textual)	'
Effective tax rates	30.00%
Sichuan Hengshuo Pharmaceutical Co Ltd [Member] | Minimum [Member]	'
Income Taxes (Textual)	'
Effective tax rates	25.00%
Sichuan Hengshuo Pharmaceutical Co Ltd [Member] | Maximum [Member]	'
Income Taxes (Textual)	'
Effective tax rates	30.00%
Jiangchuan Macrolide Project [Member] | Minimum [Member]	'
Income Taxes (Textual)	'
Effective tax rates	25.00%
Jiangchuan Macrolide Project [Member] | Maximum [Member]	'
Income Taxes (Textual)	'
Effective tax rates	30.00%

Risk_of_Concentrations_and_Cre1

Risk of Concentrations and Credit Risk (Details)	6 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
	Vendor	Vendor
Risk of Concentrations and Credit Risk (Textual)	'	'
Number of vendor	1	1
Sales [Member] | Customer [Member]	'	'
Risk of Concentrations and Credit Risk (Textual)	'	'
Concentration risk, percentage	10.00%	13.00%
Purchase [Member] | Vendor [Member]	'	'
Risk of Concentrations and Credit Risk (Textual)	'	'
Concentration risk, percentage	18.00%	46.00%
Purchase [Member] | vendor 1 [Member]	'	'
Risk of Concentrations and Credit Risk (Textual)	'	'
Concentration risk, percentage	14.00%	'
Purchase [Member] | vendor 2	'	'
Risk of Concentrations and Credit Risk (Textual)	'	'
Concentration risk, percentage	12.00%	'
Purchase [Member] | vendor 3	'	'
Risk of Concentrations and Credit Risk (Textual)	'	'
Concentration risk, percentage	11.00%	'

Earnings_Per_Share_Details

Earnings Per Share (Details) (USD $)	3 Months Ended		6 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2012
Schedule of earnings per share including dilutive effect	'	'	'	'
Net income attributed to Tianyin (numerator for diluted income per share)	$1,743,608	$1,863,950	$3,258,731	$3,405,567
Less: Dividend attributable to preferred stockholders	'	'	'	'
Net income attributable to common stockholders (numerator for basic income per share)	$1,743,608	$1,863,950	$3,258,731	$3,405,567
Weighted average common shares (denominator for basic income per share)	29,382,791	29,332,791	29,382,791	29,332,791
Effect of diluted securities:	'	'	'	'
Convertible preferred stock	'	'	'	'
Warrants	'	'	'	'
Weighted average common shares (denominator for diluted income per share)	29,382,791	29,332,791	29,382,791	29,332,791
Basic net income per share	$0.06	$0.06	$0.11	$0.12
Diluted net income per share	$0.06	$0.06	$0.11	$0.12